GGrantIndex
← Leaderboards

Christopher A French

Brigham And Women'S Hospital

$9,127,299
Attributed
$10,981,043
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,981,043 · 6

By mechanism

R01$9,011,285 · 3
U01$1,095,825 · 1
K08$696,600 · 1
R21$177,333 · 1

Top collaborators

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Chromatin

Research focus

ChromatinGrowthOncogenesHistonesBromodomainProteinsPathogenesisGenesMalignant Epithelial CellGenetic TranscriptionMalignant NeoplasmsCarcinomaEp300 GeneOncogenicSquamous Cell CarcinomaProtein ComplexComplexProgramsBindingTumorPathway InteractionsIn VitroIn VivoOncoproteins

Grant awards (34)

Genetically engineered mouse model to improve therapy of NUT carcinoma$657,032
R01 · FY2025 · CA · contact PI
Overcoming Limitations of BETInhibition in NUT Carcinoma$537,050
U01 · FY2025 · CA · contact PI
Pathogenesis and Treatment of NUT midline carcinoma$466,025
R01 · FY2025 · CA · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$629,248
R01 · FY2024 · CA · contact PI
Overcoming Limitations of BETInhibition in NUT Carcinoma$558,775
U01 · FY2024 · CA · contact PI
Pathogenesis and Treatment of NUT midline carcinoma$400,229
R01 · FY2024 · CA · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$672,468
R01 · FY2023 · CA · contact PI
Pathogenesis and Treatment of NUT midline carcinoma$421,996
R01 · FY2023 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$333,298
R01 · FY2022 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$340,100
R01 · FY2021 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$340,100
R01 · FY2020 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$329,897
R01 · FY2019 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$232,137
R01 · FY2019 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$340,100
R01 · FY2018 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$260,820
R01 · FY2018 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$331,829
R01 · FY2017 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$366,829
R01 · FY2016 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$331,163
R01 · FY2015 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$284,179
R01 · FY2014 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$37,260
R01 · FY2014 · CA · contact PI
Pathogenesis and Treatment of NUT-Midline Carcinoma$292,554
R01 · FY2013 · CA · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$290,273
R01 · FY2011 · CA · contact PI
IQGAP1 in microbial pathogenesis$445,000
R01 · FY2010 · AI · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$299,250
R01 · FY2010 · CA · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$11,748
R01 · FY2010 · CA · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$299,250
R01 · FY2009 · CA · contact PI
High throughput screen to identify inhibitors of Salmonella invasion$177,333
R21 · FY2009 · NS · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$299,250
R01 · FY2008 · CA · contact PI
Pathogenesis of NUT-Rearranged Carcinoma$299,250
R01 · FY2007 · CA · contact PI
T(15;19) in Aggressive Pediatric Carcinoma$139,320
K08 · FY2006 · CA · contact PI
T(15;19) in Aggressive Pediatric Carcinoma$139,320
K08 · FY2005 · CA
T(15;19) in Aggressive Pediatric Carcinoma$139,320
K08 · FY2004 · CA
T(15;19) in Aggressive Pediatric Carcinoma$139,320
K08 · FY2003 · CA
T(15;19) in Aggressive Pediatric Carcinoma$139,320
K08 · FY2002 · CA